|Articles|October 12, 2020

Looking for COVID-19 Symptoms Are Not Necessarily A Good Indicator of Infection

New UK population study shows majority of those who test positive did not have typical symptoms associated with the virus.

A new study coming from the United Kingdom found that 86% of patients who tested positive for COVID-19 did not have a cough, and/or fever, and/or loss of taste/smell.

This statistic comes from data collected from the Office for National Statistics Coronavirus Infection Survey pilot study. This was a large population based survey of 36,061 people looking at the association between Covid-19 symptoms and Covid-19 test results.

The data showed 115 (0.32%) people tested positive. Of the 115,16 (13.9%) reporting symptoms and in contrast, 99 (86.1%) did not report any specific symptoms on the day of the test.

"The fact that so many people who tested positive were asymptomatic on the day of a positive test result calls for a change to future testing strategies,” Irene Petersen, PhD, professor of Epidemiology and Health Informatics, University College London stated. “More widespread testing will help to capture "silent" transmission and potentially prevent future outbreaks.”

The study also includes data on people reporting a wider range of symptoms such as fatigue and shortness of breath. Of the sample who tested positive, 27 (23.5%) were symptomatic and 88 (76.5%) were asymptomatic on the day of the test.

The research included a population sample of who were tested between April 26 and June 27. The findings were published in the journal Clinical Epidemiology.

"Pooled testing could be one way to help implement a widespread testing strategy where several tests are pooled together in one analysis to save time and resources on individual testing,” Petersen explained. “This strategy would be an efficient way to test when the overall prevalence is low as negative pooled samples can quickly show a large group of people are not infectious."

The authors did note that several studies have highlighted a lower proportion of individuals testing positive for Covid-19 are asymptomatic, however, the prevalence of asymptomatic cases varies substantially, possibly due to the sampling and the settings of the study.


Related to this article

Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
FAQ: Shamonda Virus
As France confirms the first documented human Shamonda virus infection, a fatal encephalitis in a stem cell transplant recipient, this FAQ explains what the virus is, where it has spread, how the case was diagnosed, how the patient was likely infected and what clinicians should watch for.
ID Week Highlights Part 1
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.